Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-951 SAD in Parkinson's Disease
NCT03033498Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2017
- Primary completion
- Jun 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of foslevodopa and foscarbidopa in Parkinson's disease (PD) (8 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration of Levodopa, Time to Maximum Observed Plasma Concentration of Levodopa and 4 more. Started May 2017; status: completed.
02
Drugs
foslevodopafoscarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03033498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03033498.